Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

FDA special emergency program will accelerate COVID-19 therapies

As the COVID-19 pandemic spreads rapidly throughout the world, the urgency of finding a treatment has magnified. The Coronavirus Treatment Acceleration Program (CTAP), a special emergency program created by the Food and Drug Administration (FDA), will accelerate COVID-19 therapies by using all available methods to rapidly deliver new treatments to patients, says GlobalData, a leading […]
Read more

KidneyIntelX™ to assess risk of adverse kidney events in COVID-19 patients

Following the announcement that Renalytix AI’s KidneyIntelX™ platform will be used to assess the risk of kidney injury in COVID-19 patients; Azadeh Laffafian, Medical Device Analyst at GlobalData, a leading data and analytics company, offers her view: “There are multiple reports of acute kidney injury in hospitalized COVID-19 patients. Additionally, patients with prior kidney disease are […]
Read more

Recovered patient antibody treatments against COVID-19 underway

With the continuation of the COVID-19 pandemic and possible vaccines approximately one year away from launch, the race to find a treatment for the disease continues. A growing number of pharmaceutical companies have begun work on recovered patients’ antibody treatments for COVID-19. As monoclonal antibody (mAb) drugs are some of the top sellers in the […]
Read more

Stimulatory cell receptors key to three-drug combinations in future immuno-oncology treatments, says GlobalData

Emerging three-drug combinations are poised to redefine the immuno-oncology treatment paradigm in advanced malignancies with high unmet need, according to GlobalData, a leading data and analytics company. The oncology market is saturated with new drugs that target the immune system, however, these only target part of the problem caused by cancer’s ability to hide from […]
Read more

MSCs enter COVID-19 treatment race with best source and optimal dosing key unanswered questions

Several companies developing mesenchymal stromal cells (MSCs) for COVID-19 saw significant stock movement after announcing their plans, and early data is indeed encouraging for further exploration in clinical trials, according to reporting from Manasi Vaidya, Pharma Writer for the Investigative News team at GlobalData, a leading data and analytics company. Yet, there are also several limitations with […]
Read more

Neurimmune and Ethris recovered patients antibody treatment for COVID-19 could remove plasma treatment bottleneck

As the COVID-19 pandemic continues to spread, collaborations between companies with differing areas of expertise could accelerate the availability of a treatment for the disease. Neurimmune and Ethris’ collaboration could produce a recovered patient antibody treatment that could be rapidly delivered to patients without requiring continued recovered patients’ plasma donations or continued verification of the antibodies […]
Read more

COVID-19 pandemic interferes with treatments in female health space

The American Society of Reproductive Medicine (ASRM) issued guidance on fertility treatments during COVID-19 and called for suspension of most new treatment cycles such as IVF. Furthermore, The European Society of Human Reproduction and Embryology (ESHRE) has advised women not to undergo IVF treatment during the pandemic. This may impact the demand and 2Q sales […]
Read more

BARDA supports Moderna’s COVID-19 vaccine candidate but many obstacles ahead to confirm potential of mRNA vaccine strategy

The Biomedical Advanced Research and Development Authority (BARDA) has agreed to provide up to $483m to assist Moderna in developing its COVID-19 vaccine candidate, but reporting from Reynald Castañeda, Pharma Writer for the Investigative News team at GlobalData, a leading data and analytics company, shows that experts are cautious about mRNA-1273’s potential to trigger sufficient immunogenicity. Castañeda says: “From […]
Read more

Nanoparticles may be used to make safer and more effective RNA-based therapeutics

A number of pharmaceutical companies have RNA-based therapeutics and vaccines in development for COVID-19. However, there are a number of safety concerns around the use of viral vectors with these therapies and the use of lipid-based nanoparticles may offer a safer alternative, says GlobalData, a leading data and analytics company. Kathryn Whitney, MSc, Director of Thematic Analysis, comments: “RNA has received considerable research attention in recent years and has the […]
Read more

Nanotechnology being used by researchers in fight against COVID-19

With the accelerating global burden from the COVID-19 pandemic, researchers are rapidly searching for a viable vaccine or therapeutic to combat the global public health emergency. One of the approaches being investigated is the use of nanotechnology, says GlobalData, a leading data and analytics company. An international collaboration has developed a nanotechnology approach to halting […]
Read more

Novartis’ Isturisa provides new hope to Cushing’s disease market

Novartis’ Isturisa (osilodrostat) leads recent innovation in Cushing’s disease (CD) with its latest Food and Drug Administration (FDA) approval, says GlobalData, a leading data and analytics company. Isturisa, an 11-beta-hydroxylase inhibitor, is the first FDA approved drug to directly target overproduction of cortisol, the hormone of issue in CD. The drug has proven to be […]
Read more

Government initiatives minimize Indian pharma industry manufacturing and supply chain disruptions amid Covid-19 crisis, says GlobalData

India’s coronavirus (Covid-19) lockdown has impacted the manufacturing and supply chain operations of pharmaceuticals despite pharmaceutical manufacturing being considered an essential service and excluded from the lockdown. However, government initiatives have helped to minimize disruptions to pharmaceutical manufacturing and the supply chain, says GlobalData, a leading data and analytics company. The issues faced by the […]
Read more

Global age-related macular degeneration market will more than double in size by 2028

The pharmaceutical market for age-related macular degeneration (AMD) was worth an estimated $8.6bn across the nine major markets (9MM*) in 2018. This is expected to grow to $18.7bn in 2028 at a modest compound annual growth rate (CAGR) of 8.1%, according to GlobalData, a leading data and analytics company. GlobalData’s latest report, ‘Age-Related Macular Degeneration: Global Drug Forecast and Market Analysis to 2028’, explains that growth in the market will be driven by the entry of longer-acting anti-angiogenic therapies and the launch […]
Read more

Healthcare sector witnesses decline in deal activity during the week ended April 12

The number of deals announced in the global healthcare sector (including pharmaceuticals and medical equipment) declined by 28% during the week ended April 12, 2020 compared to the previous week, according to GlobalData’s deals database. Aurojyoti Bose, Analyst at GlobalData, comments: “The decline was subsequent to two consecutive weeks of growth in deal activity. Deal activity in the healthcare sector has remained inconsistent due to uncertainty and volatile market conditions since the coronavirus outbreak.” Deal activity declined in the key markets such as the US and China during the week ended April 12. The announcement of venture financing, partnership, licensing agreement and merger and […]
Read more

Protease inhibitors could benefit from being trialled with milder cases of COVID-19

AbbVie was one of the first companies to donate its combination of HIV protease inhibitors Aluvia (lopinavir/ritonavir), also known as Kaletra, to help China treat patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, more recent investigations show that treatment with lopinavir-ritonavir does not actually provide a substantial benefit beyond standard care*, says GlobalData, a leading data and analytics company. Angad Lotay, MPharm, Infectious Diseases Analyst at GlobalData, […]
Read more
1 … 97 98 99 100 101 … 110